1.Mid-Ventricular Obstructive Hypertrophic Cardiomyopathy Associated with an Apical Aneurysm: Evaluation of Possible Causes of Aneurysm Formation.
Yuichi SATO ; Naoya MATSUMOTO ; Shinro MATSUO ; Shunichi YODA ; Shigemasa TANI ; Yuji KASAMAKI ; Tadateru TAKAYAMA ; Satoshi KUNIMOTO ; Satoshi SAITO
Yonsei Medical Journal 2007;48(5):879-882
Mid-ventricular obstructive hypertrophic cardiomyopathy (MVOHCM) is a rare type of cardiomyopathy, associated with apical aneurysm formation in some cases. We report a patient presenting with ventricular fibrillation, an ECG with an above normal ST segment, and elevated levels of cardiac enzymes but normal coronary arteries. Left ventriculography revealed a left ventricular obstruction without apical aneurysm. There was a significant pressure gradient between the apical and basal sites of the left ventricle. Cine magnetic resonance imaging (MRI), performed on the 10th hospital day, showed asymmetric septal hypertrophy, mid-ventricular obstruction, and an apical aneurysm with a thrombus. The first evaluation by contrast-enhanced imaging showed a subendocardial perfusion defect and delayed enhancement. It was speculated that the intraventricular pressure gradient, due to mid- ventricular obstruction, triggered myocardial infarction, which subsequently resulted in apical aneurysm formation.
Cardiomyopathy, Hypertrophic/complications/*diagnosis
;
Coronary Angiography
;
Echocardiography, Doppler
;
Heart Aneurysm/*diagnosis/etiology
;
Humans
;
Hypertrophy, Left Ventricular/complications/*diagnosis
;
Magnetic Resonance Imaging, Cine
;
Male
;
Middle Aged
;
Myocardial Ischemia/complications/diagnosis
2.Endoscopic treatment or balloon-occluded retrograde transvenous obliteration is safe for patients with esophageal/gastric varices in Child-Pugh class C end-stage liver cirrhosis
Keiji YOKOYAMA ; Ryo YAMAUCHI ; Kumiko SHIBATA ; Hiromi FUKUDA ; Hideo KUNIMOTO ; Kazuhide TAKATA ; Takashi TANAKA ; Shinjiro INOMATA ; Daisuke MORIHARA ; Yasuaki TAKEYAMA ; Satoshi SHAKADO ; Shotaro SAKISAKA
Clinical and Molecular Hepatology 2019;25(2):183-189
BACKGROUND/AIMS: There is a controversy about the availability of invasive treatment for esophageal/gastric varices in patients with Child-Pugh class C (CP-C) end-stage liver cirrhosis (LC). We have evaluated the validity of invasive treatment with CP-C end-stage LC patients. METHODS: The study enrolled 51 patients with CP-C end-stage LC who had undergone invasive treatment. The treatment modalities included endoscopic variceal ligation in 22 patients, endoscopic injection sclerotherapy in 17 patients, and balloon-occluded retrograde transvenous obliteration (BRTO) in 12 patients. We have investigated the overall survival (OS) rates and risk factors that contributed to death within one year after treatment. RESULTS: The OS rate in all patients at one, three, and five years was 72.6%, 30.2%, and 15.1%, respectively. The OS rate in patients who received endoscopic treatment and the BRTO group at one, three, and five years was 67.6%, 28.2% and 14.1% and 90.0%, 36.0% and 18.0%, respectively. The average of Child-Pugh scores (CPS) from before treatment to one month after variceal treatment significantly improved from 10.53 to 10.02 (P=0.003). Three significant factors that contributed to death within one year after treatment included the presence of bleeding varices, high CPS (≥11), and high serum total bilirubin levels (≥4.0 mg/dL). CONCLUSIONS: The study demonstrated that patients with a CPS of up to 10 and less than 4.0 mg/dL of serum total bilirubin levels may not have a negative impact on prognosis after invasive treatment for esophageal/gastric varices despite their CP-C end-stage LC.
Balloon Occlusion
;
Bilirubin
;
Endoscopy
;
Esophageal and Gastric Varices
;
Hemorrhage
;
Humans
;
Hypertension, Portal
;
Ligation
;
Liver Cirrhosis
;
Liver
;
Prognosis
;
Risk Factors
;
Sclerotherapy
;
Varicose Veins